Artemether+Lumefantrine Suspension 15mg+90mg/5ml

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
  • Artemether+Lumefantrine Suspension 15mg+90mg/5ml
Find Similar Products

Basic Info.

Model NO.
AMC16008
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Suspension
Type
Powder
Pharmaceutical Technology
Biological Products
Shelf Life
3 Years
OEM/ODM Brand
Available
Delivery Time
30-50 Days
Quality Standard
in House
Transport Package
60ml, 1 Bottle/Box
Specification
15mg+90mg/5ml
Trademark
Medipharm
Origin
China
HS Code
3003601000
Production Capacity
5000000 Per Month

Product Description

Indication: The combination of Art mether+Lume fantrine is used to treat certain kinds of malaria infections (a serious infection that is spread by mosquitoes in certain parts of the world and can cause death). Art mether+Lume fantrine should not be used to prevent malaria. Art mether+Lume fantrine is in a class of medications called antimalarials. It works by killing the organisms that cause malaria. Precautions & Warning: Some antimalarials (e.g., halofantrine, quinine, quinidine) including Coartem Tablets have been associated with prolongation of the QT interval on the electrocardiogram. Coartem Tablets should be avoided in patients: with congenital prolongation of the QT interval (e.g., long QT syndrome) or any other clinical condition known to prolong the QTc interval such as patients with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease. with a family history of congenital prolongation of the QT interval or sudden death. with known disturbances of electrolyte balance, e.g., hypokalemia or hypomagnesemia. receiving other medications that prolong the QT interval, such as class IA (quinidine, procainamide, disopyramide), or class III (amiodarone) antiarrhythmic agents; antipsychotics (pimozide, ziprasidone);antidepressants; certain antibiotics (macrolide antibiotics, fluoroquinolone antibiotics, imidazole, and triazole antifungal agents); certain non-sedating antihistaminics (terfenadine, astemizole), or cisapride. receiving medications that are metabolized by the cytochrome enzyme CYP2D6 which also have cardiac effects (e.g., flecainide, imipramine, amitriptyline, clomipramine) Contra-indications: Hypersensitivity Known hypersensitivity to arte mether, lume fantrine, or to any of the excipients of Coartem Tablets Treatment: There is no information on overdoses of Coartem Tablets higher than the doses recommended for treatment. In cases of suspected overdosage, symptomatic and supportive therapy, which would include ECG and bloodelectrolyte monitoring, should be given as appropriate.

 
Production:
Artemether+Lumefantrine Suspension 15mg+90mg/5ml

 

Inspection:
Artemether+Lumefantrine Suspension 15mg+90mg/5ml
Loading:
Artemether+Lumefantrine Suspension 15mg+90mg/5ml
Certificates:
Artemether+Lumefantrine Suspension 15mg+90mg/5ml


 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier